These platforms have been increasingly employed for Alzheimer’s disease (AD) biomarker detection, particularly amyloid-beta (Aβ) peptides and tau protein, using voltammetric, impedimetric, and transistor-based formats. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.